Human C-reactive protein induces endothelial dysfunction in biobreeding diabetic rats

Diabetes and Vascular Disease Research

Volumn 10, Issue 6, 2013, Pages 550-553

  Jialal, Ishwarlal ^a,b   Kaur, Harmeet ^a   Devaraj, Sridevi ^c   Smith, Gerred ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

C reactive protein; endothelial dysfunction; inflammation; type 1 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; GLUCOSE; HUMAN SERUM ALBUMIN; INTERCELLULAR ADHESION MOLECULE 1; PROSTAGLANDIN F1 ALPHA; TOLL LIKE RECEPTOR 4; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; INFLAMMATION; MACROPHAGE; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT;

C-REACTIVE PROTEIN; ENDOTHELIAL DYSFUNCTION; INFLAMMATION; TYPE 1 DIABETES MELLITUS;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; RATS; RATS, INBRED BB; TIME FACTORS;

EID: 84886066213     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113503971     Document Type: Article

References (23)

1. Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular event in diabetes. Diabetes Care. 2004 ; 27: 889-894
2. Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes. 2009 ; 58: 926-933
3. Soinio M, Marnemi J, Laakso M, et al. High sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. Diabetes Care. 2006 ; 29: 329-333
4. Libby P, Nathan DM, Abraham K, et al. Report of the National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases: working group on cardiovascular complications of type 1 diabetes mellitus. Circulation. 2005 ; 11: 3489-3493
5. Devaraj S, Glaser N, Griffen S, et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006 ; 55: 774-779
6. Mordes JP, Bortell R, Blankenhorn EP, et al. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J. 2004 ; 45: 278-291
7. Jialal I, Kaur H, Devaraj S. Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats. J Diabetes Complications. 2013 ; 27: 23-28
8. Jialal I, Devaraj S. Antisense to PKC-alpha and p47phox attenuates the pro-inflammatory effects of human C-reactive protein in macrophages of biobreeding diabetic rats. Diab Vasc Dis Res. 2012 ; 9: 315-319
9. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007 ; 262: 157-172
10. Devaraj S, Xu D, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003 ; 107: 398-404
11. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. 2009 ; 55: 229-238
12. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006 ; 113: 2135-2150
13. Devaraj S, Dasu MR, Singh U, et al. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis. 2009 ; 203: 67-74
14. Dasu MR, Devaraj S, Du Clos TW, et al. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res. 2007 ; 48: 509-512
15. Devaraj S, Jialal I. CRP polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol. 2011 ; 31: 1397-1402
16. Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein. Clin Chem. 2009 ; 55: 206-208
17. Jialal I, Devaraj S, Siegel D. CRP induces hypertension in animal models: homo sapiens says no. Hypertens Res. 2011 ; 34: 801-802
18. Wynants M, Quarck R, Ronisz A, et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2012 ; 40: 886-894
19. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002 ; 105: 1890-1896
20. Guan H, Wang P, Hui R, et al. Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem. 2009 ; 55: 274-284
21. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation. 2003 ; 108: 1676-1678
22. Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009 ; 206: 61-68
23. Devaraj S, Davis B, Simon SI, et al. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol. 2006 ; 291: H1170 - H1176